Aktivieren Sie Javascript in Ihrem Browser, um unsere Webseite optimal zu nutzen.

SirtAct (CAY-10591)

Act 839699-72-8 2-Amino-N-cyclopentyl-1-(3-methoxypropyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide

1 image

Produktnummer ABIN7233290

145,38 €

Zzgl. Versandkosten 20,00 € und MwSt

Lieferung nach: Deutschland

Lieferung in 6 bis 10 Werktagen

Kurzübersicht für SirtAct (CAY-10591) (ABIN7233290)

Applikation

Activation (Act)

Chemical Name

2-Amino-N-cyclopentyl-1-(3-methoxypropyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide

Verwendungszweck

SIRT1 activator

Produktmerkmale

Sirt1 activator (233 % at 10 μM)1 Suppresses TNFα release from THP-1 cells and stimulates adipogenesis in 3T3L1 cells1. SIRT1 stimulation by SirtAct leads to decreased tissue factor mediated thrombogenicity in mice2. Inhibits NFκB activation and reduces inflammatory cytokine production in lamina propria mononuclear cells from IBD patients3. Prevents and cures experimental colitis in a mouse model3.

Reinheit

>98 %

Formel

C20H25N5O2

Löslichkeit

Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 20 mg/ml).
Geldanamycin- FITC
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Geldanamycin
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Radicicol
Inh 12772-57-5

Geldanamycin- Biotin
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Herbimycin A
Inh 70563-58-5 [(2R,3S,5S,6R,7S,8E,10S,11S,12E,14E)-2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate

17-GMB-APA-GA
Inh [(3R,5S,6R,7S,10S,11S)-21-[3-[4-(2,5-dioxopyrrol-1-yl)butanoylamino]propylamino]-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate

TEMPO
Inh 2564-83-2 2,2,6,6-Tetramethylpiperidine 1-oxyl, 2,2,6,6-Tetramethyl-1-piperidinyloxy, free radical, (2,2,6,6-Tetramethyl-1-piperidinyl)oxidanyl, 1,1,5,5-tetramethylpentamethylene nitroxide, 2,2,6,6-Tetramethylpiperidine-1-oxyl

Triacsin C
Inh 76896-80-5 (3E)-1-Oxo-3-[(2E,4E,7E)-2,4,7-undecatrien-1-ylidene]triazane

TPCK
Inh 402-71-1 N-(4-Chloro-3-oxo-1-phenyl-2-butanyl)-4-methylbenzenesulfonamide

Staurosporine
Inh 62996-74-1 (2S,3R,4R,6R)-3-Methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one

Applikationshinweise

Optimal working dilution should be determined by the investigator.

Beschränkungen

Nur für Forschungszwecke einsetzbar
Format

Powder

Lagerung

-20 °C

Informationen zur Lagerung

-20°C
Hintergrund

CAY10591,Posttranslational modification,Epigenetics,Chromatin,Protein deacetylase,Diabetes,Inflammation,Cytokine,NFkappaB

Molekulargewicht

367.46

CAS-Nummer

839699-72-8